Key result
Intravenous melagatran administered for 4 to 6 days in patients with acute DVT achieved stable plasma concentrations and was well tolerated with no clinically significant bleeding.
Why the study?
Does intravenous melagatran provide safe and effective anticoagulation and thrombus regression compared to unfractionated heparin in patients with acute proximal DVT?
RCT (n=48)
randomised
Does intravenous melagatran provide safe and effective anticoagulation and thrombus regression compared to unfractionated heparin in patients with acute proximal DVT?
Intravenous melagatran achieves stable, dose-dependent anticoagulation and promotes thrombus regression safely in patients with acute proximal DVT.
Answers are grounded in this paper and cite their sources.
IV melagatran offers stable, bleed-free anticoagulation in acute DVT; extends direct thrombin inhibitor data ahead of oral transition trials.
Forty-eight patients with acute proximal deep vein thrombosis (DVT) were randomised to intravenous infusions for 4 to 6 days with melagatran, a novel synthetic low molecular weight thrombin inhibitor, or unfractionated heparin adjusted by the activated partial thromboplastin time (APTT). The aim of the study was to investigate the pharmacokinetics, pharmacodynamics and the safety of melagatran therapy at three different doses. Steady-state plasma concentrations were rapidly achieved and maintained throughout the infusion period. The mean plasma concentrations in the low, medium and high dose groups were 0.17, 0.31 and 0.53 micromol/l, respectively. The prolongation of APTT was stable during the melagatran infusions and correlated to the plasma concentration. Phlebographically verified regression of thrombus size measured as decrease in Marder score was seen after 4 to 6 days in 8 of 12 patients, 6 of 12 patients and 5 of 11 patients in the low, medium and high dose groups of melagatran and in 5 of the heparin-treated patients. In the low dose group with melagatran, thrombus extension was seen in one patient. At the dose levels studied, melagatran was well tolerated with no clinically significant bleeding problems, suggesting that melagatran could safely be given to patients suffering from DVT.
No takes yet. Share an insight, caveat, or question.
Eriksson et al. (1999) conducted an RCT in acute proximal deep vein thrombosis (DVT) (n=48). Melagatran vs. Unfractionated heparin was evaluated on Pharmacokinetics, pharmacodynamics and safety. Intravenous melagatran administered for 4 to 6 days in patients with acute DVT achieved stable plasma concentrations and was well tolerated with no clinically significant bleeding.
Synapse has enriched 10 related papers. Consider them for comparative context: